Archive for the ‘jama’ Category
JAMA journal quietly replaces diabetes drug commentary after learning co-author is working for drugmaker
JAMA Internal Medicine has replaced a commentary they published last week on the risks of two diabetes drugs, but you wouldn’t know the new version was a replacement.
One change is a correction about whether Byetta and Januvia carry so-called “black box” warnings from the FDA. The original sentence:
Because both drugs already carry US Food and Drug Administration (FDA) black box warnings for the risk of pancreatitis, why is this study important?
It now reads: Read the rest of this entry »
JAMA has issued its first-ever Expression of Concern over a 2007 study of hip protectors in the elderly that came under scrutiny from Federal regulators.
Coming clean: A major figure in cardiology publishes a lengthy conflict of interest correction in JAMA
Authors’ financial disclosures can be a thorny issue for scientific journals. There’s often confusion over just what should be listed as a conflict of interest, and when relationships are revealed after papers are published, lack of disclosure sometimes leads to corrections.